Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

How to ‘digitally and socially’ win over your legal / regula...

Colleen Broughton, William Reese and Jim Walker of the Cadient Group, a leading digital healthcare marketing agency, share their top tips to creating a positive relationship with your legal / regulatory team. Social media in the pharmaceutical industry continues to generate a great deal of interest, discussion and debate...

Articles

In APAC, the biosimilar market is set to grow

Syamala Ariyanchira shares her opinions on the growth opportunities in the biosimilar market within emerging markets, with a particular focus on China, India and Korea. The market sentiments towards biosimilars vary widely between the regulated and the semi- and unregulated markets. While regulated markets adopt...

Articles

Drug shortage strategies

Darshan Kulkarni highlights the problems associated with drug shortages in healthcare. This is intended to be a discussion of how healthcare providers are dealing with drug shortages. This blog will give a front line view...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.